Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis

Waldemar E. Wysokinski, Izabela Gosk-Bierska, Eddie L. Greene, Diane Grill, Heather Wiste, Robert D. McBane

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: To determine whether treatment guidelines for patients with lower-extremity venous thrombosis (DVT) could be applied to patients with renal vein thrombosis (RVT). The rates of recurrent venous thrombosis and survival for patients with these 2 diseases were compared. Study Design: Inception cohort of individuals was identified with their first lifetime incident of RVT. Recurrent thrombosis and survival were compared with those for patients with DVT in a case-control fashion. Setting & Participants: All patients with a diagnosis of RVT at Mayo Clinic from 1980 to 2000. Outcomes & Measures: Survival and recurrent venous thrombosis rates were compared with those for patients with DVT. Survival rates were also compared with those for US white residents. Results: 218 patients (mean age, 55 ± 19 years) were included (35% women). Malignancy (66%) and nephrotic syndrome (20%) were the most common underlying causes. Warfarin was prescribed for 74 patients (46% with lifelong therapy). During a mean follow-up of 42 ± 57 months (768 patient-years), there were 8 recurrent venous thrombotic events (1.0/100 patient-years). This recurrence rate was less than that for patients with DVT (P < 0.001). Survival was lower compared with patients with DVT or age- and sex-matched US white residents (P < 0.001). Active malignancy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.2 to 4.7) and infection (HR, 2.4; 95% CI, 1.4 to 4.0) were associated with poor survival. Survival was influenced positively by warfarin therapy (HR, 0.53; 95% CI, 0.31 to 0.90). Limitations: Retrospective nonrandomized study. Conclusions: RVT represents a distinct clinical entity with unique recurrence and survival rates. The finding of RVT should prompt a thorough evaluation for an underlying renal malignancy. Oral anticoagulation therapy may be associated with a survival advantage.

Original languageEnglish (US)
Pages (from-to)224-232
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume51
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Renal Veins
Thrombosis
Survival
Venous Thrombosis
Warfarin
Confidence Intervals
Survival Rate
Recurrence
Neoplasms
Nephrotic Syndrome
Therapeutics
Lower Extremity
Retrospective Studies

Keywords

  • nephrotic syndrome
  • renal cell cancer
  • Renal vein thrombosis

ASJC Scopus subject areas

  • Nephrology

Cite this

Wysokinski, W. E., Gosk-Bierska, I., Greene, E. L., Grill, D., Wiste, H., & McBane, R. D. (2008). Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis. American Journal of Kidney Diseases, 51(2), 224-232. https://doi.org/10.1053/j.ajkd.2007.10.030

Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis. / Wysokinski, Waldemar E.; Gosk-Bierska, Izabela; Greene, Eddie L.; Grill, Diane; Wiste, Heather; McBane, Robert D.

In: American Journal of Kidney Diseases, Vol. 51, No. 2, 02.2008, p. 224-232.

Research output: Contribution to journalArticle

Wysokinski, WE, Gosk-Bierska, I, Greene, EL, Grill, D, Wiste, H & McBane, RD 2008, 'Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis', American Journal of Kidney Diseases, vol. 51, no. 2, pp. 224-232. https://doi.org/10.1053/j.ajkd.2007.10.030
Wysokinski, Waldemar E. ; Gosk-Bierska, Izabela ; Greene, Eddie L. ; Grill, Diane ; Wiste, Heather ; McBane, Robert D. / Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis. In: American Journal of Kidney Diseases. 2008 ; Vol. 51, No. 2. pp. 224-232.
@article{04903c0b115649eaa9877f97377a67ff,
title = "Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis",
abstract = "Background: To determine whether treatment guidelines for patients with lower-extremity venous thrombosis (DVT) could be applied to patients with renal vein thrombosis (RVT). The rates of recurrent venous thrombosis and survival for patients with these 2 diseases were compared. Study Design: Inception cohort of individuals was identified with their first lifetime incident of RVT. Recurrent thrombosis and survival were compared with those for patients with DVT in a case-control fashion. Setting & Participants: All patients with a diagnosis of RVT at Mayo Clinic from 1980 to 2000. Outcomes & Measures: Survival and recurrent venous thrombosis rates were compared with those for patients with DVT. Survival rates were also compared with those for US white residents. Results: 218 patients (mean age, 55 ± 19 years) were included (35{\%} women). Malignancy (66{\%}) and nephrotic syndrome (20{\%}) were the most common underlying causes. Warfarin was prescribed for 74 patients (46{\%} with lifelong therapy). During a mean follow-up of 42 ± 57 months (768 patient-years), there were 8 recurrent venous thrombotic events (1.0/100 patient-years). This recurrence rate was less than that for patients with DVT (P < 0.001). Survival was lower compared with patients with DVT or age- and sex-matched US white residents (P < 0.001). Active malignancy (hazard ratio [HR], 2.4; 95{\%} confidence interval [CI], 1.2 to 4.7) and infection (HR, 2.4; 95{\%} CI, 1.4 to 4.0) were associated with poor survival. Survival was influenced positively by warfarin therapy (HR, 0.53; 95{\%} CI, 0.31 to 0.90). Limitations: Retrospective nonrandomized study. Conclusions: RVT represents a distinct clinical entity with unique recurrence and survival rates. The finding of RVT should prompt a thorough evaluation for an underlying renal malignancy. Oral anticoagulation therapy may be associated with a survival advantage.",
keywords = "nephrotic syndrome, renal cell cancer, Renal vein thrombosis",
author = "Wysokinski, {Waldemar E.} and Izabela Gosk-Bierska and Greene, {Eddie L.} and Diane Grill and Heather Wiste and McBane, {Robert D.}",
year = "2008",
month = "2",
doi = "10.1053/j.ajkd.2007.10.030",
language = "English (US)",
volume = "51",
pages = "224--232",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical Characteristics and Long-term Follow-up of Patients With Renal Vein Thrombosis

AU - Wysokinski, Waldemar E.

AU - Gosk-Bierska, Izabela

AU - Greene, Eddie L.

AU - Grill, Diane

AU - Wiste, Heather

AU - McBane, Robert D.

PY - 2008/2

Y1 - 2008/2

N2 - Background: To determine whether treatment guidelines for patients with lower-extremity venous thrombosis (DVT) could be applied to patients with renal vein thrombosis (RVT). The rates of recurrent venous thrombosis and survival for patients with these 2 diseases were compared. Study Design: Inception cohort of individuals was identified with their first lifetime incident of RVT. Recurrent thrombosis and survival were compared with those for patients with DVT in a case-control fashion. Setting & Participants: All patients with a diagnosis of RVT at Mayo Clinic from 1980 to 2000. Outcomes & Measures: Survival and recurrent venous thrombosis rates were compared with those for patients with DVT. Survival rates were also compared with those for US white residents. Results: 218 patients (mean age, 55 ± 19 years) were included (35% women). Malignancy (66%) and nephrotic syndrome (20%) were the most common underlying causes. Warfarin was prescribed for 74 patients (46% with lifelong therapy). During a mean follow-up of 42 ± 57 months (768 patient-years), there were 8 recurrent venous thrombotic events (1.0/100 patient-years). This recurrence rate was less than that for patients with DVT (P < 0.001). Survival was lower compared with patients with DVT or age- and sex-matched US white residents (P < 0.001). Active malignancy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.2 to 4.7) and infection (HR, 2.4; 95% CI, 1.4 to 4.0) were associated with poor survival. Survival was influenced positively by warfarin therapy (HR, 0.53; 95% CI, 0.31 to 0.90). Limitations: Retrospective nonrandomized study. Conclusions: RVT represents a distinct clinical entity with unique recurrence and survival rates. The finding of RVT should prompt a thorough evaluation for an underlying renal malignancy. Oral anticoagulation therapy may be associated with a survival advantage.

AB - Background: To determine whether treatment guidelines for patients with lower-extremity venous thrombosis (DVT) could be applied to patients with renal vein thrombosis (RVT). The rates of recurrent venous thrombosis and survival for patients with these 2 diseases were compared. Study Design: Inception cohort of individuals was identified with their first lifetime incident of RVT. Recurrent thrombosis and survival were compared with those for patients with DVT in a case-control fashion. Setting & Participants: All patients with a diagnosis of RVT at Mayo Clinic from 1980 to 2000. Outcomes & Measures: Survival and recurrent venous thrombosis rates were compared with those for patients with DVT. Survival rates were also compared with those for US white residents. Results: 218 patients (mean age, 55 ± 19 years) were included (35% women). Malignancy (66%) and nephrotic syndrome (20%) were the most common underlying causes. Warfarin was prescribed for 74 patients (46% with lifelong therapy). During a mean follow-up of 42 ± 57 months (768 patient-years), there were 8 recurrent venous thrombotic events (1.0/100 patient-years). This recurrence rate was less than that for patients with DVT (P < 0.001). Survival was lower compared with patients with DVT or age- and sex-matched US white residents (P < 0.001). Active malignancy (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.2 to 4.7) and infection (HR, 2.4; 95% CI, 1.4 to 4.0) were associated with poor survival. Survival was influenced positively by warfarin therapy (HR, 0.53; 95% CI, 0.31 to 0.90). Limitations: Retrospective nonrandomized study. Conclusions: RVT represents a distinct clinical entity with unique recurrence and survival rates. The finding of RVT should prompt a thorough evaluation for an underlying renal malignancy. Oral anticoagulation therapy may be associated with a survival advantage.

KW - nephrotic syndrome

KW - renal cell cancer

KW - Renal vein thrombosis

UR - http://www.scopus.com/inward/record.url?scp=38349043747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349043747&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2007.10.030

DO - 10.1053/j.ajkd.2007.10.030

M3 - Article

VL - 51

SP - 224

EP - 232

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -